{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-26-000115","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2026-07-30T10:32:37+00:00","discovered_at":"2026-07-30T10:35:00.345271+00:00","generated_at":"2026-07-30T10:35:12.588068+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agios Q2 2026 mitapivat revenue $44.7M; net loss $100.7M; FDA Priority Review for sickle cell sNDA","bullets":["Mitapivat worldwide net revenue $44.7M (Q2 2026) vs $12.5M (Q2 2025); U.S. $40.9M, ex-U.S. $3.8M.","FDA granted Priority Review for mitapivat sNDA in sickle cell disease; PDUFA date Nov 1, 2026.","Licensed cevidoplenib from Oscotec for ITP; up to $1B peak U.S. sales potential; $25M up-front payment.","Discontinued tebapivat in LR-MDS and sickle cell disease; advancing AG-236 to Phase 2/3 for polycythemia vera.","Cash, equivalents, and marketable securities $964.8M as of June 30, 2026; net loss $100.7M vs $112.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-26-000115","json":"https://secwatch.observer/filing/0001439222-26-000115.json","markdown":"https://secwatch.observer/filing/0001439222-26-000115.md","text":"https://secwatch.observer/filing/0001439222-26-000115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000115/0001439222-26-000115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000115/agio-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T10:35:12.588068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}